New study by Public Health England (PHE) shows for the first time that 2 doses of the COVID-19 vaccines are highly effective against the B.1.617.2 variant first identified in India.
Vaccine effectiveness against symptomatic disease from the B.1.617.2 variant is similar after 2 doses compared to the B.1.1.7 (Kent) variant dominant in the UK, and we expect to see even higher levels of effectiveness against hospitalisation and death.
The study found that, for the period from 5 April to 16 May:
- the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the B.1.617.2 variant 2 weeks after the second dose, compared to 93% effectiveness against the B.1.1.7 variant
- 2 doses of the AstraZeneca vaccine were 60% effective against symptomatic disease from the B.1.617.2 variant compared to 66% effectiveness against the B.1.1.7 variant
- both vaccines were 33% effective against symptomatic disease from B.1.617.2, 3 weeks after the first dose compared to around 50% effectiveness against the B.1.1.7 variant
The analysis included data for all age groups from 5 April to cover the period since the B.1.617.2 variant emerged. It included 1,054 people confirmed as having the B.1.617.2 variant through genomic sequencing, including participants of several ethnicities. Data published on Thursday 20 May for vaccine effectiveness covered the period since December for those aged over 65.
The difference in effectiveness between the vaccines after 2 doses may be explained by the fact that rollout of second doses of AstraZeneca was later than for the Pfizer-BioNTech vaccine, and other data on antibody profiles show it takes longer to reach maximum effectiveness with the AstraZeneca vaccine.
Health and Social Care Secretary Matt Hancock said:
This new evidence is groundbreaking – and proves just how valuable our COVID-19 vaccination programme is in protecting the people we love.
source-Public Health England press office